Spyre Therapeutics, Inc.
HealthcareNASDAQ:SYRE · NASDAQ Capital Market
+$0.02 today
Vol 0.79M · Avg 1.16M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-21.7%
avg -78.6%
ROIC
-29.1%
avg -66.7%
ROA
-20.0%
avg -58.4%
Analysis
ROA is currently the strongest return metric at -20.0% versus its period average of -58.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Cameron Turtle DPHIL | Chief Executive Officer & Director | $1.15M | — | 36 | $608,983.00 | 1.01% |
Sheldon Sloan | Chief Medical Officer | $778,560.00 | — | 67 | $313,334.00 | 0.52% |
Scott L. Burrows | Chief Financial Officer | $758,800.00 | — | 49 | $374,857.00 | 0.62% |
Heidy Abreu King-Jones | Chief Legal Officer & Corporate Secretary | $758,800.00 | — | 43 | $140,000.00 | 0.23% |
James Myers | Vice President of Quality & Compliance | — | — | — | — | — |
Melissa Cooper | Senior Vice President of People | — | — | — | — | — |
Janet Gunzner-Toste | Senior Vice President of Operations | — | — | — | — | — |
Justin LaFountaine | Senior Vice President of Corporate Development | — | — | — | — | — |
Brian Connolly | Chief Technical Officer | — | — | — | — | — |
Eric McIntyre | Vice President of Finance & Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
44
$20.71M
Net Sentiment
$20.71M
Net selling
Most Active
Turtle Cameron
22 transactions
1–10 of 44
Analysis
Insiders reported 0 buys worth $0.00 and 44 sells worth $20.71M over the last 12 months. That adds up to net selling of $20.71M. Turtle Cameron was the most active insider with 22 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | -13.9% | +33.2% (12yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Recent growth has been strongest in Revenue at -13.9% over three years. Forward estimates point to Revenue at +33.2% (12yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
Zymeworks Inc.
NASDAQ:ZYME
$1.68B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.60B
Ardelyx, Inc.
NASDAQ:ARDX
$1.41B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.36B
Maze Therapeutics, Inc.
NASDAQ:MAZE
$1.33B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.13B
Upstream Bio, Inc.
UPB
$331.96M
Who manages SYRE?
Spyre Therapeutics, Inc. (SYRE) lists 10 active executives. The top listed executive is Scott L. Burrows, Chief Financial Officer.
Are SYRE insiders buying or selling?
Recent insider activity shows net buying of $48.42M.
Explore More
Continue the stock analysis
Jump to another research area for this company.